Catenin Beta 1 (Beta Catenin or CTNNB1) – Drugs in Development, 2021

Catenin Beta 1 (Beta Catenin or CTNNB1) – Catenin beta-1 or β-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.

Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 18 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 6 and 6 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Non Malignant Disorders, Dermatology, Gastrointestinal and Respiratory which include indications Colorectal Cancer, Melanoma, Solid Tumor, Unspecified Cancer, Breast Cancer, Hepatocellular Carcinoma, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, Benign Tumor, Blood Cancer, Brain Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Head And Neck Cancer, Hemangiomas, Hematological Tumor, Hepatic (Liver) Tumor, Idiopathic Pulmonary Fibrosis, Leukemia, Liver Cirrhosis, Lung Cancer, Neuroendocrine Tumors, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Prostate Cancer and Scar.

The latest report Catenin Beta 1 – Drugs In Development, 2021, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)

– The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aileron Therapeutics Inc

Circle Pharma Inc

Dicerna Pharmaceuticals Inc

Fog Pharmaceuticals Inc

iBeCa Therapeutics

MD2 Biosciences Inc

PRISM Pharma Co Ltd

Propanc Biopharma Inc

Sapience Therapeutics Inc

Stemsynergy Therapeutics Inc

Sumitomo Dainippon Pharma Oncology, Inc

Venn Therapeutics LLC

WntRx Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview

Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development

Aileron Therapeutics Inc

Circle Pharma Inc

Dicerna Pharmaceuticals Inc

Fog Pharmaceuticals Inc

iBeCa Therapeutics

MD2 Biosciences Inc

PRISM Pharma Co Ltd

Propanc Biopharma Inc

Sapience Therapeutics Inc

Stemsynergy Therapeutics Inc

Sumitomo Dainippon Pharma Oncology, Inc

Venn Therapeutics LLC

WntRx Pharmaceuticals Inc

Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles

Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBI-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exisulind - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nefopam hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides for Hepatoblastoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRI-724 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Beta Catenin and BCL9 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Beta Catenin for Colorectal Cancer and Brain Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Catenin for Unspecified Cancers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Catenin for Unspecified Cancers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CTNNB1 for Unspecified Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit CTNNB1 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WX-024 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products

Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones

Featured News & Press Releases

Dec 21, 2020: Propanc Biopharma receives first granted patent for method to treat cancer stem cells from Australian Patent Office

Jun 17, 2020: Sapience Therapeutics to present data on ß-catenin antagonist program at 2020 AACR Virtual Annual Meeting II

Apr 14, 2020: Propanc Biopharma receives first allowance for key patent family from Australian Patent Office

Jan 21, 2020: Propanc Biopharma receives advance overseas finding from Innovation and Science Australia

Oct 21, 2019: Propanc Biopharma illustrates novel mode of action of PRP, suppressing EMT Pathways and Metastasis in Cancer Patients

Aug 21, 2019: Propanc Biopharma receives granted US patent covering additional composition claims for PRP

Aug 12, 2019: Propanc Biopharma publishes key data in peer reviewed journal confirming anti-cancer stem cell effects of Proenzymes

Aug 08, 2019: Propanc Biopharma completes development of bio-analytical assay method to quantify PRP active ingredients in preparation for first-in-human study

Jul 15, 2019: Propanc Biopharma provides update on preparation of PRP for clinical trial application submission and recently completed reverse stock split

Jun 27, 2019: Propanc Biopharmas Intellectual Property portfolio undergoes rapid growth

May 06, 2019: Propanc Biopharma appoints Dr. Ralf Brandt to its scientific advisory board

Apr 26, 2019: Announcement of the signing of a joint R & D agreement and commencement of development activities regarding “Research and development of innovative antifibrotic drugs to improve the life prognosis of cirrhosis”

Mar 25, 2019: Propanc Biopharma initiates development of bio-analytical assay in preparation for human trials

Mar 13, 2019: Propanc Biopharma receives notice of allowance for additional claims from foundation patent in the U.S.

Dec 20, 2018: Novel development drug OP-724 (PRI-724) for the treatment of cirrhosis is published on Nature Outline

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Indications, 2021 (Contd..1)

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Aileron Therapeutics Inc, 2021

Pipeline by Circle Pharma Inc, 2021

Pipeline by Dicerna Pharmaceuticals Inc, 2021

Pipeline by Fog Pharmaceuticals Inc, 2021

Pipeline by iBeCa Therapeutics, 2021

Pipeline by MD2 Biosciences Inc, 2021

Pipeline by PRISM Pharma Co Ltd, 2021

Pipeline by Propanc Biopharma Inc, 2021

Pipeline by Sapience Therapeutics Inc, 2021

Pipeline by Stemsynergy Therapeutics Inc, 2021

Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, 2021

Pipeline by Venn Therapeutics LLC, 2021

Pipeline by WntRx Pharmaceuticals Inc, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports